39 results about "Multiglycosidorum tripterygii" patented technology

The invention belongs to the technical field of medicinal preparations and relates to a tripterygium glycoside-containing micro-emulsified gel transdermal preparation and a preparation method thereof. The preparation method is characterized in that a gel matrix is added into microemulsion and the mixture is further processed into the tripterygium glycoside-containing micro-emulsified gel transdermal preparation. The tripterygium glycoside-containing micro-emulsified gel transdermal preparation comprises: by mass, 0.1 to 15% of tripterygium glycoside, 15 to 20% of one or more surfactants, 30 to 40% of one or more auxiliary surfactants, 15 to 25% of oil phases, 15 to 25% of water, 0.5 to 2% of one or more transdermal absorption promoters, and 0.5 to 5% of one or more gel base materials. Thetripterygium glycoside-containing micro-emulsified gel transdermal preparation is semitransparent or transparent, has nattier blue opalescence and a pH value of 6 to 10 and can form micro-emulsion having particle sizes of 10 to 100nm, can be processed into pasters so that drug transdermal delivery is realized, has low skin irritation, can be prepared by the simple preparation method, and has stable quality and good drug transdermal absorption promotion performances.

The invention relates to a method for reducing an organic solvent residue in tripterygium glycoside. Organic solvents (mainly comprising ethanol and chloroform) are adopted to carry out collection, extraction, chromatography and the like in a production technology of the tripterygium glycoside, and the problem of an unstable index of the organic solvent residue in the tripterygium glycoside is generated at present. The method comprises the following steps: dissolving a tripterygium glycoside semi-finished product by absolute ethyl alcohol, and fully agitating to evenly dissolve; concentrating the obtained tripterygium glycoside ethanol solution, and pumping out at reduced pressure after recovering ethanol, so as to obtain a powdery dry product; and obtaining the tripterygium glycoside product by adopting a method of combining warm water precipitation with low-temperature vacuum drying. By adopting the method, the organic solvent residue in the tripterygium glycoside can be effectively reduced, and the quality is stable.

The invention discloses a method for extracting tripchlorolide from tripterygium wilfordii front segment extractum. At present, tripchlorolide with little amount is obtained by employing a multi-time chromatography method to perform chromatographic separation on tripterygium glycosides or an extraction product directly extracted from tripterygium wilfordii raw material by ethanol and perform rotating thin layer chromatography, and the method cannot be used to large-scale production at all. The method provided by the invention comprises: utilizing a hydrophilic solvent low alcohol / ketone to perform extraction on the tripterygium wilfordii front segment extractum, separating majority of lipophilic impurities in the front-segment extractum, then extracting with trichloromethane to separate some other non-target products with relatively small solubility in the low alcohol / ketone, then performing chromatographic separation purification, and finally utilizing chloroform to perform recrystallization. The method provided by the invention is simple and practicable in separation and purification technology, is suitable for industrialized large-scale production; and the prepared tripchlorolide is applicable to develop new drugs.

The invention provides a tripterygium wilfordii medicinal material and a method for determining wilforlidea in a tripterygium wilfordii polyglycosides tablet. The method comprises the following stepsof taking an ethanol solution of 0.1 mg.mL<-1> of wilforlidea as a reference substance solution; acquiring a corresponding volume ratio range by establishing and optimizing normal hexane, ethyl acetate, ethanol and water of a solvent system so that a distribution coefficient K of the wilforlidea in the solvent system is 0.5-2; optimizing and controlling a rotating speed of a liquid-liquid distribution chromatographic separation column and a flowing speed of a mobile phase, and detecting the tripterygium wilfordii medicinal material and the method for determining the wilforlidea in the tripterygium wilfordii polyglycosides tablet by combining high performance liquid chromatography. The method is simple in operation process, high in specificity and good in reproducibility, separation cost isgreatly reduced, a wilforlidea chromatographic separation degree is high, a product recovery rate is high too, a sample dosage is small, stability is good, precision is high, qualitative and quantitative accuracy is high too, and quality of the tripterygium wilfordii medicinal material and the tripterygium wilfordii polyglycosides tablet can be effectively evaluated.

The invention relates to the field of traditional Chinese medicine, and discloses a method for synergizing and attenuating toxicity of tripterygium glycosides and tripterygnee monomers, in which tripterygium polyglycosides or tripterygnee monomers are compatible with resveratrol as a medicine application. The technology of the present invention uses the tripterygium wilfordii main component tripterygium glycosides or tripterygium and resveratrol compatibility to play a synergistic and detoxifying effect. Resveratrol can increase the IC50 of tripteryne on intestinal epithelial cells, and reduce the IC50 of tripteryne on basophilic leukemia cells; it can reduce the apoptosis of intestinal epithelial cells induced by tripteryne; and further found that Veratrol-related effects work by activating Sirt protein. The invention can greatly expand the use of tripterygium wilfordii, tripterygium glycosides and tripterygium wilfordii, reduce the side effects of clinical medication, and reduce pain for clinical patients.

The invention discloses a new polyglycoside of tripterygium wilfordii with low toxicity, which is obtained by chemically processing the polyglycoside of tripterygium wilfordii and adding triptolide triol. The invention also discloses the application of the new tripterygium wilfordii polyglycoside with low toxicity in medicine. The tripterygium wilfordii new polyglycoside of the present invention can effectively relieve nephrotic syndrome kidney pathological damage and proteinuria, improve body inflammation level, have obvious therapeutic effect on nephrotic syndrome, and have low toxicity and long-lasting effect.

The invention discloses a compound preparation for reducing hepatotoxicity of tripterygium glycoside tablets, and a preparation method of the compound preparation. The compound preparation comprises silibin meglumine tablets and the tripterygium glycoside tablets. The compound preparation has the efficacies of protecting the liver for detoxification, tonifying the kidney and strengthening the spleen; the dosage of tripterygium glycosides can be obviously increased; a better curative effect is achieved; and meanwhile, the hepatotoxicity of the tripterygium glycosides is obviously reduced. In addition, according to the compound preparation, the fast release of silibin meglumine and the long-acting stable release of tripterygium glycosides can be realized, and the treatment effect is furtherimproved. In addition, the preparation method provided by the invention has the advantages that the operation is simple; the cost is low; the preparation method is suitable for industrial production;and the application prospects are good.

The invention relates to chemical structure and a preparation method of a compound 2R-cardiospermin-5-p-hydroxybenzoate as well as an application of the compound in preparing medicines for treating rheumatoid arthritis. The 2R-cardiospermin-5-p-hydroxybenzoate, as a novel compound purified and prepared from a conventional traditional Chinese medicine, namely Sorbaria sorbifolia (L.) A. Brown, by the inventor, can be used for obviously inhibiting PEG2 and NO levels in serum of a mouse with adjuvant arthritis, and the compound is close to tripterygium glycosides at an equivalent dosage in activity; therefore, the compound can be used for preparing the medicines for treating and resisting the rheumatoid arthritis. The chemical structure and the preparation method of the compound as well as anti-RA (rheumatoid arthritis) activity of the compound are disclosed for the first time, therefore outstanding substantive features are guaranteed.

The invention provides a system for determining the individual effectiveness of treating rheumatoid arthritis by tripterygium glycosides tablets through the expression amount of various miRNAs (microRibonucleic Acid). The various miRNAs comprise hsa-miR-550b-2-5p, hsa-miR-4797-5p, hsa-miR-6509-5p and hsa-miR-378g. The invention further provides a molecular marker for determining the individual effectiveness of treating the rheumatoid arthritis by the tripterygium glycosides tablets, application of the molecular marker to preparation of a kit for determining the individual effectiveness of treating the rheumatoid arthritis by the tripterygium glycosides tablets, and application of a reagent for detecting the expression amount of the molecular marker to the preparation of the kit for determining the individual effectiveness of treating the rheumatoid arthritis by the tripterygium glycosides tablets. The invention provides a high-specificity and high-sensitivity molecular marker and a curative effect predication model for individual diagnosis and treatment of the rheumatoid arthritis.

The invention relates to a chemical structure and preparing method of the compound sutherlandin-5-cis-p-coumarate and application of the compound to preparation of drugs for treating rheumatoid arthritis. Sutherlandin-5-cis-p-coumarate is a novel compound prepared from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. through purification by the applicant of the invention. The compound can remarkably suppress the level of PEG2 and NO in serum of adjuvant arthritis rats. The activity of the compound is close to that of tripterygium glycosides of the same dose, and the compound can be used for preparing drugs for treating rheumatoid arthritis. The chemical structure, preparing method and anti-RA activity of the compound are disclosed for the first time, thus having prominent and substantive features.

The present invention relates to the chemical structure and preparation method of a compound Sutherlandin-5-p-hydroxybenzoate, and the application of the compound in the preparation of medicines for treating rheumatoid arthritis. Sutherlandin‑5‑p‑hydroxybenzoate is a new compound purified and prepared by the applicant of the present invention from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. It can significantly inhibit the PEG in the serum of rats with adjuvant arthritis 2 and NO level, and its activity is stronger than that of tripterygium glycosides in the same dose, and can be used to prepare medicines for treating rheumatoid arthritis. The chemical structure, preparation method and anti-RA activity of the compound are disclosed for the first time, so it has outstanding substantive features.

The present invention relates to the chemical structure and preparation method of a compound 2S-cardiospermin-5-benzoate, and the application of the compound in the preparation of drugs for treating rheumatoid arthritis. 2S-cardiospermin-5-benzoate is a new compound purified and prepared by the applicant of the present invention from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. It can significantly inhibit the PEG in the serum of rats with adjuvant arthritis. 2 and NO level, and its activity is stronger than that of tripterygium glycosides in the same dose, and can be used to prepare medicines for treating rheumatoid arthritis. The chemical structure, preparation method and anti-RA activity of the compound are disclosed for the first time, so it has outstanding substantive features.

The invention provides an application of trillium tschonoskii total saponins in preparation of a medicine for treating rheumatoid arthritis. The effect of the trillium tschonoskii total saponins on adjuvant-induced arthritis model rat inflammation is researched from an NOD-like receptor protein 3 / cysteine aspartic protease 1 pathway. The SD rats are randomly divided into a blank group, a model group, a tripterygium glycosides group, a trillium tschonoskii total saponin low-dose group, a trillium tschonoskii total saponin medium-dose group and a trillium tschonoskii total saponin high-dose group, and each group comprises six rats. The result shows that compared with the Control group, the foot swelling degree, the arthritis score, the serum TNF-alpha, IL-1beta and IL-6 levels of the AA group, the NLRP3 protein expression level in synovial tissues and the NLRP3, ASC and Caspase-1 protein levels in ankle joints are all remarkably improved; knee joint synovial cell proliferation, interstitial edema and inflammatory cell infiltration of the AA group rats; and after treatment with TG and TTM with different doses, the indexes are all improved to different degrees.

The present invention relates to the medical use of Capers or Capers extracts, specifically provides Capers or Capers extracts in the preparation of medicines for reducing tripterygium wilfordii, tripterygium glycosides or triptolide hepatotoxicity or The application in health products also provides a composition and its preparation for preventing and treating rheumatoid arthritis, glomerulonephritis, nephrotic syndrome, lupus erythematosus, dry eye syndrome, Behcet's disease, eczema, psoriasis , leprosy, scabies, ringworm, Hashimoto's thyroid or tumor medicine or health care products, the composition comprises component i) and component ii), and the component i) is selected from: Capers or the extract of capers; the component ii) is selected from: tripterygium glycosides or triptolide.

The invention relates to a chemical structure and preparing method of the compound 2S-cardiospermin-5-cis-p-coumarate and application of the compound to preparation of drugs for treating rheumatoid arthritis. 2S-cardiospermin-5-cis-p-coumarate is a novel compound prepared from the traditional Chinese medicine Sorbaria sorbifolia (L.) A. Brown. through purification by the applicant of the invention. The compound can remarkably suppress the level of PEG2 and NO in serum of adjuvant arthritis rats. The activity of the compound is close to that of tripterygium glycosides of the same dose, and the compound can be used for preparing drugs for treating rheumatoid arthritis. The chemical structure, preparing method and anti-RA activity of the compound are disclosed for the first time, thus having prominent and substantive features.

The invention relates to a method for reducing residual organic solvents in tripterygium glycosides. In the production process of tripterygium glycosides, organic solvents (mainly ethanol and chloroform) must be used for extraction, extraction, chromatography, etc. Currently, there is a problem of unstable residual indicators of organic solvents in tripterygium glycosides. The present invention dissolves the semi-finished tripterygium glycosides with absolute ethanol, and fully stirs to make the dissolution uniform; concentrates the obtained tripterygium glycosides ethanol liquid, recovers the ethanol, and decompresses and drains to obtain a powdery dry product; then uses warm water to precipitate Combined with the low-temperature vacuum drying method, the tripterygium glycosides finished product is obtained. The invention can effectively reduce the residual organic solvent in the tripterygium glycosides, and has stable quality.

The invention discloses an application of phellinus igniarius and tripterygium glycosides in delaying a focal segmental glomerulosclerosis process. The combined phellinus igniarius and tripterygium glycosides can significantly reduce urine protein, reduce serum creatinine and urea nitrogen of rats, reduce serum triglyceride, cholesterol and low-density lipoprotein, and reduce the amount of creatine kinase, creatine kinase isozyme and glutamic-pyruvic transaminase. The phellinus igniarius water decoction is combined with the tripterygium glycosides for use, so that the toxicity of the tripterygium glycosides can be reduced and the heart injury can be improved on the basis of ensuring the original effects of the tripterygium glycosides on relieving the renal function injury of FSGS rats, reducing blood fat and the like, and the application prospect is wide.

The invention relates to the technical field of medicines for conditioning rheumatoid arthritis, and discloses an application of total flavonoids of radix tetrastigme in rheumatoid arthritis treating medicines. The medicines are capable of conditioning the rheumatoid arthritis. A preparation process of the total flavonoids of radix tetrastigme comprises the following steps: prpearing 10-30kg of coarse powder of tubers of radix tetrastigme; conducting reflux extraction for 3 times with the addition of ethanol which is 65-75% in volume percentage; combining extracting solutions, decompressing the combined extracting solutions and recovering ethanol; keeping an obtained solution for a whole night and filtering the solution; extracting an obtained filtrate for three times by virtue of petroleum ether and conducting degreasing; processing the greased filtrate by virtue of a polyamide column; eluting the column sequentially by virtue of water and ethanol which is 90-95% in volume percentage; and decompressing an eluent of the ethanol which is 90-95% in volume percentage and recovering ethanol until a dried material is obtained, namely the total flavonoids of radix tetrastigme. At present, tripterygium glycosides, as a traditional Chinese medicine, can take a relatively good effect on treating the rheumatoid arthritis, however the tripterygium glycosides can cause various toxic and side effects, such as relatively serious injury to female ovaries and male sperms, and subsequently, clinical application is limited. According to the invention, the total flavonoids of radix tetrastigme, on treating the rheumatoid arthritis, is good in effect and free from toxic and side effects.